1. Turawa E, Awotiwon O, Dhansay MA, et al. Prevalence of Anaemia, Iron Deficiency, and Iron Deficiency Anaemia in Women of Reproductive Age and Children under 5 Years of Age in South Africa (1997-2021): A Systematic Review. Int J Environ Res Public Health. 2021;18(23):12799.
2. Khan L. Anemia in Childhood. Pediatr Ann. 2018;47(2):e42-e47.
3. Allali S, Brousse V, Sacri AS, Chalumeau M, de Montalembert M. Anemia in children: prevalence, causes, diagnostic work-up, and long-term consequences. Expert Rev Hematol. 2017;10(11):1023-1028.
4. Blanc L, Wolfe LC. General conditions of hemolytic disease, red cell membrane and enzyme defects. In: Lanzkowsky P, editor. Manual of pediatric hematology and oncology. 7th ed. San Diego, CA:Elsevier Academic Press; 2022. pp 125-150.
5. Oski FA, Brugnara C, Nathan DG. A diagnostic approach to the anemic patient. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), W.B. Saunders, 2003. p.409.
6. Jamwal M, Sharma P, Das R. Laboratory Approach to Hemolytic Anemia.<em>Indian J Pediatr</em>. 2020;87(1):66-74
7. Davis BH, Ornvold K, Bigelow NC. Flow cytometric reticulocyte maturity index: a useful laboratory parameter of erythropoietic activity in anemia. Cytometry. 1995;22(1):35-39
8. Phillips J, Henderson AC. Hemolytic Anemia: Evaluation and Differential Diagnosis. Am Fam Physician. 2018;98(6):354-361
9. Khandros E, Kwiatkowski JL. Hemoglobinopathies. In: Lanzkowsky P, editor. Manual of pediatric hematology and oncology. 7th ed. San Diego, CA:Elsevier Academic Press; 2022. pp 161-192
10. Pecker LH, Lanzkron S. Sickle Cell Disease. Ann Intern Med. 2021;174(1):ITC1-ITC16.
11. Barabino GA, Platt MO, Kaul DK. Sickle cell biomechanics. Annu Rev Biomed Eng. 2010;12:345-367.
12. Piccin A, Murphy C, Eakins E, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019;102(4):319-330.
13. Hirtz D, Kirkham FJ. Sickle Cell Disease and Stroke. Pediatr Neurol. 2019;95:34-41
14. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. Published 2018 Mar 15.
15. Sant&#39;Ana PG, Araujo AM, Pimenta CT, et al. Clinical and laboratory profile of patients with sickle cell anemia. Rev Bras Hematol Hemoter. 2017;39(1):40-45.
16. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published correction appears in JAMA. 2014 Nov 12;312(18):1932] [published correction appears in JAMA. 2015 Feb 17;313(7):729]. JAMA. 2014;312(10):1033-1048.
17. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355.
18. Antmen B, Karakaş Z, Yeşilipek MA, et al. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM). Eur J Haematol. 2019;102(2):123-130.
19. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am J Hematol. 2019;94(1):55-61.
20. Herity LB, Vaughan DM, Rodriguez LR, Lowe DK. Voxelotor: A Novel Treatment for Sickle Cell Disease.<em>Ann Pharmacother</em>. 2021;55(2):240-245.
21. Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.<em>N Engl J Med</em>. 2018;379(3):226-235.
22. Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: An update. Cytotherapy. 2018;20(7):899-910.,Abraham AA, Tisdale JF. Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood. 2021;138(11):932-941.
23. Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. Lancet. 2022;399(10343):2310-2324
24. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155-167,
25. Viprakasit V, Ekwattanakit S. Clinical Classification, Screening and Diagnosis for Thalassemia. Hematol Oncol Clin North Am. 2018;32(2):193-211.
26. Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016;38 Suppl 1:32-40.
27. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-3488.
28. Aydinok Y. Iron Chelation Therapy as a Modality of Management. Hematol Oncol Clin North Am. 2018;32(2):261-275.).
29. Strocchio L, Locatelli F. Hematopoietic Stem Cell Transplantation in Thalassemia. Hematol Oncol Clin North Am. 2018;32(2):317-328.
30. Farashi S, Harteveld CL. Molecular basis of &alpha;-thalassemia. Blood Cells Mol Dis. 2018;70:43-53.
31. Horvei P, MacKenzie T, Kharbanda S. Advances in the management of &alpha;-thalassemia major: reasons to be optimistic. Hematology Am Soc Hematol Educ Program. 2021;2021(1):592-599.
32. Mohandas N. Inherited hemolytic anemia: a possessive beginner&#39;s guide. Hematology Am Soc Hematol Educ Program. 2018;2018(1):377-381.
33. G&uuml;ng&ouml;r A, Yaralı N, Fettah A, Ok-Bozkaya İ, &Ouml;zbek N, Kara A. Hereditary spherocytosis: Retrospective evaluation of 65 children. Turk J Pediatr. 2018;60(3):264-269.
34. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008;372(9647):1411-1426.
35. Manciu S, Matei E, Trandafir B. Hereditary Spherocytosis - Diagnosis, Surgical Treatment and Outcomes. A Literature Review. Chirurgia (Bucur). 2017;112(2):110-116.
36. Zamora EA, Schaefer CA. Hereditary Spherocytosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 4, 2022.
37. Wu Y, Liao L, Lin F. The diagnostic protocol for hereditary spherocytosis-2021 update. J Clin Lab Anal. 2021;35(12):e24034.
38. Kalfa TA. Diagnosis and clinical management of red cell membrane disorders.<em>Hematology Am Soc Hematol Educ Program</em>. 2021;2021(1):331-340.
39. Aksu T. Hereditary Red Blood Cell Enzymopathies. J Pediatr Acad 2021; 2: 9-13.
40. Johnson S, Grace RF, Despotovic JM. Diagnosis, monitoring, and management of pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2022;69(8):e29696.).
41. Grace RF, Bianchi P, van Beers EJ, et al. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018;131(20):2183-2192.
42. Laas C, Lambert C, Senior McKenzie T, et al. Improving the laboratory diagnosis of pyruvate kinase deficiency. Br J Haematol. 2021;193(5):994-1000.
43. Grace RF, Barcellini W. Management of pyruvate kinase deficiency in children and adults. Blood. 2020;136(11):1241-1249.).
44. Harcke SJ, Rizzolo D, Harcke HT. G6PD deficiency: An update. JAAPA. 2019;32(11):21-26.
45. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020;136(11):1225-1240.
46. Roper D, Layton M, Rees D, et al. Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. Br J Haematol. 2020;189(1):24-38.
47. Pfeffer DA, Ley B, Howes RE, et al. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis [published correction appears in PLoS Med. 2020 Jul 24;17(7):e1003311]. PLoS Med. 2020;17(5):e1003084. Published 2020 May 14.
48. Garcia AA, Koperniku A, Ferreira JCB, Mochly-Rosen D. Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives. Trends Pharmacol Sci. 2021;42(10):829-844.